Fast Track buys a rolling file, not a faster clock

This blog has already drawn two lines around what a special FDA status actually buys: speed without an approval, in breakthrough designation’s speed without an approval, and an asset that outlives the drug that earned it, in a priority review voucher that isn’t tied to one drug. Fast Track designation draws a third line, and it’s the one most often blurred with the other two: what it actually grants a sponsor isn’t a faster review clock at all.

The designation targets how a drug gets developed, not how fast it gets reviewed

Section 506(b) of the Act, 21 U.S.C. 356(b) — added by section 112 of the 1997 FDA Modernization Act — lets FDA designate a drug Fast Track if it’s intended to treat a serious or life-threatening condition and nonclinical or clinical data show the potential to address an unmet medical need. FDA’s May 2014 guidance, Expedited Programs for Serious Conditions — Drugs and Biologics, is explicit about where the designation actually operates: on the development program and the application process, not on the review clock a complete marketing application runs against once it’s filed.

The feature that does the real work is a rolling application

What a sponsor gets for holding Fast Track status is the option to submit a new drug or biologics application in sections, rather than all at once — a completed nonclinical module, say, filed and under FDA review well before the clinical section is ready to go. FDA reviews each section as it arrives instead of waiting on the complete package. Fast Track also buys more frequent formal meetings with the review division during development, to work out the plan and the data a later application will need. Both benefits land before the application is filed. Neither one touches the PDUFA goal date that starts running only once the complete application actually is.

The only clock built into the designation itself is sixty days

A sponsor can request Fast Track designation with the IND itself, or at any point afterward through FDA’s pre-NDA or pre-BLA meeting — there’s no single fixed filing window the way a patent certification has one. Once the request is in, the statute gives FDA sixty days to grant or deny it. That’s the only hard deadline Fast Track itself runs on; how the rolling submission actually gets scheduled, section by section, is worked out between sponsor and division rather than fixed by the statute.

Breakthrough inherits every Fast Track feature and adds a higher bar

Breakthrough Therapy designation, created by FDASIA in 2012, doesn’t replace Fast Track — it carries every Fast Track feature automatically and layers on two more: more intensive FDA guidance on an efficient development program, starting as early as Phase 1, and the direct involvement of senior agency managers. The cost of reaching that tier is evidentiary: Fast Track only needs the potential to address an unmet need, where Breakthrough needs preliminary clinical evidence that the drug may show substantial improvement over available therapies on a clinically significant endpoint. A drug can hold both designations at once, but Breakthrough is the one that actually requires clinical data already in hand.

Priority review is a separate decision, made at a separate moment

Priority review doesn’t attach during development at all. It’s assigned when FDA files a complete marketing application, and all it changes is which of FDA’s own internal goal dates the review runs against — a six-month target instead of the standard ten-month one. A drug can be Fast Track and priority review at once, the first shaping how the application gets built and the second shaping how long FDA aims to take once it’s built, but treating them as one decision collapses two calls made at two different points in a drug’s file.

Where this meets the file

A designation tracker that records “Fast Track granted” as a single checkbox has nowhere to put the two facts that actually decide how a rolling application gets managed: which sections FDA has agreed to review as submitted, and the sixty-day response the original request is still running against if it hasn’t been answered yet. A designation-tracking template that keeps a drug’s Fast Track, Breakthrough, and priority-review statuses as three separate fields, each with its own grant date, is previewed in the launch catalog alongside this week’s other drug-lifecycle templates. If your program tracks a rolling submission differently, the shelf takes that correction directly.